Business Wire

Introducing The Continental Edge: The Easternmost Direct Interconnectivity Point Between Europe and the United States

Jaa

Introducing the Continental Edge, the easternmost direct interconnection point between Europe and the United States. Four companies, focused on four key areas of services, have partnered to offer the first holistic solution that delivers best-of-breed colocation, connectivity, internet, and subsea cable solutions. The partnership is an amalgamation of companies brought to market collectivity by 1025Connect (for colocation); Aqua Comms (transatlantic subsea connectivity); DE-CIX (the leading Internet Peering Exchange), and Epsilon (a global network service provider providing on-demand SDN connectivity solutions).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005054/en/

The Continental Edge Map (Graphic: Business Wire)

The Continental Edge Map (Graphic: Business Wire)

1025Connect’s data center and colocation facilities serves as the central point where Aqua Comms' AEC-1 cable lands and Epsilon and DE-CIX platforms are available. Any customer connected to Epsilon’s leading SDN platform, Infiny, can now design, provision, and manage network connectivity from its dense European footprint across AEC-1, the shortest subsea route between the United States and Ireland. This consists of inter datacenter, cloud or internet exchange connections, including to the leading internet exchange DE-CIX. DE-CIX customers can leverage the company’s direct peering options or its GlobePEER Remote capabilities to reach more than 1,100 unique global networks with nearly 200 locally available directly from 1025Connect’s Long Island data center.

All four partners will be attending Capacity Europe from 23-25, October 2018. To request a meeting with 1025Connect, Aqua Comms, DE-CIX, or Epsilon at Capacity Europe please email: continentaledge@imillerpr.com.

1025Connect

1025Connect is Long Island’s premier network-neutral Meet-Me Room for network interconnection and colocation, located at 1025 Old Country Road in Westbury, New York. This facility is renowned for its ability to connect global subsea systems to terrestrial networks with the optional ability to bypass Manhattan for greater network diversity and serves as host to the easternmost peering point in the New York metro area, enabling easier access and delivery of content distributed to the Continental Edge.

Aqua Comms

Aqua Comms DAC is an Irish Carriers’ Carrier specialising in building and operating submarine cable systems and supplying fibre pairs, spectrum and capacity networking solutions to the global media, content and carrier markets. It is the owner/operator of America Europe Connect-1 (AEC-1) and CeltixConnect-1 and continues to build on its vision of efficient submarine infrastructure ownership with membership of the HAVFRUE consortium and development of CeltixConnect-2 and North Sea Connect, bridging the Northern Atlantic between North America and Europe. To learn more about Aqua Comms and its portfolio of subsea cable systems visit http://www.aquacomms.com/.

DE-CIX North America

With access to DE-CIX North America’s leading Internet Exchange Platform, operators gain more control of their networks and access to world-class content providers, as well as IP transit, Virtual Private Network (VPN) and blackholing services to mitigate the effects of DDoS attacks. DE-CIX’s presence at 1025Connect provides direct access to the most robust, meshed IXP serving the New York metro market. Now customers can access close to 200 unique networks across the largest Internet Exchange Point and the only Open-IX certified IXP in the New York Market. Extend reach across the DE-CIX platform through its GlobePEER Remote solution to reach over 800 unique networks at DE-CIX Frankfurt, the world’s leading Internet Exchange by data traffic.

Epsilon

Epsilon is a global Cloud-centric Network Service Provider, extending carrier grade connectivity services to the world’s communications and cloud ecosystems. The company offers smart networking capabilities through its simple and powerful SDN platform, Infiny, that combines on-demand infrastructure, automation, web-based portals and APIs to give partners friction-free access to global connectivity.

Situated within 1025Connect, Infiny is now the easternmost SDN exchange in the USA. A connection to Epsilon provides customers access to an interconnected mesh of 100 datacenters across North America, Europe, Asia and the Middle East. Leveraging Aqua Comms’ network across the Atlantic coupled with direct connections to the leading Cloud and Internet Exchange (IX) providers including DE-CIX North America, Epsilon delivers orchestrated connectivity for advanced IX peering, cloud and content networking.

Contact information

Ilissa Miller
iMiller Public Relations
Tel: +1.866.307.2510
Email: pr@imillerpr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EETTiedote

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EETTiedote

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EETTiedote

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EETTiedote

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EETTiedote

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin

Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EETTiedote

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme